Geographic atrophy and factors associated with disease progression among Medicare Advantage enrollees [0.03%]
地萎缩症及其病情进展的影响因素（基于美国Medicare Advantage参保人的数据）
Vishal Saundankar,Mark Borns,Kelly Broderick et al.
Vishal Saundankar et al.
Background: Geographic atrophy (GA) is a form of advanced age-related macular degeneration (AMD) that can cause irreversible vision impairment and is responsible for approximately 20% of legal blindness in the United Stat...
Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with schizophrenia in the United States [0.03%]
美国成人精神分裂症患者注射艾利哌唑的预算影响分析研究
Vakaramoko Diaby,Shubhram Pandey,Vassiki Sanogo et al.
Vakaramoko Diaby et al.
Background: Schizophrenia is a chronic psychiatric disorder, affecting 1.1% of the adult population in 2020 in the United States. Antipsychotic treatment is commonly used in schizophrenia management to help reduce the lik...
Cost-effectiveness of caplacizumab in immune thrombotic thrombocytopenic purpura in the United States [0.03%]
美国获得性免疫性血栓性血小板减少性紫癜患者使用caplacizumab的卫生经济学分析
Sean D Sullivan,Shruti Chaturvedi,Preety Gautam et al.
Sean D Sullivan et al.
Background: Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening thrombotic microangiopathy. Caplacizumab is the only treatment approved by the European Medicines Agency and the US Food and Drug A...
Impact of social determinants of health on esketamine nasal spray initiation among patients with treatment-resistant depression in the United States [0.03%]
美国难治性抑郁症患者使用 esketamine 鼻喷雾剂的初始治疗受社会健康因素的影响研究
Kristin Clemens,Maryia Zhdanava,Amanda Teeple et al.
Kristin Clemens et al.
Background: Disparities in mental health care access and health outcomes based on sociodemographic factors in the United States have been extensively documented. However, there is limited knowledge regarding these socioec...
Pharmacoequity measurement framework: A tool to reduce health disparities [0.03%]
药学公平测量框架：减少健康差异的工具
Pranav M Patel,Utibe R Essien,Laura Happe
Pranav M Patel
Pharmacoequity is a health system and policy goal of ensuring equitable access to high-quality medications for all individuals, regardless of factors such as race, ethnicity, socioeconomic status, or resource availability to reduce health d...
Correction [0.03%]
改正通知书
Area deprivation index impact on type 2 diabetes outcomes in a regional health plan [0.03%]
地区剥夺指数对区域保健计划中2型糖尿病结果的影响
Taylor N Laffey,David Marr,Ashley Modany et al.
Taylor N Laffey et al.
Background: Rates of attainment of high-quality diabetes care have been shown to be lower for those living in more disadvantaged and rural areas. Diabetes management relies on access to care and is impacted by physical, s...
Olajumoke A Olateju,Jieni Li,J Douglas Thornton et al.
Olajumoke A Olateju et al.
Background: The incidence of melanoma has increased significantly in the past few decades, posing a significant public health challenge. However, there is an evidence gap regarding the marginal costs of treating melanoma....
Patient perceptions of their experience with comprehensive medication reviews: A framework for continued quality improvement [0.03%]
患者对其综合用药审查体验的看法：持续质量改进的框架
Melissa Castora-Binkley,Shalini Selvarajah,Mariana Felix et al.
Melissa Castora-Binkley et al.
Background: A comprehensive medication review (CMR) is an annual service offered to eligible Medicare Part D beneficiaries as a component of the Medication Therapy Management program. However, little is known about the mo...
Imetelstat for anemia in lower-risk myelodysplastic syndromes: A summary from the Institute for Clinical and Economic Review's California Technology Assessment Forum [0.03%]
低风险骨髓增生异常综合征贫血患者使用Imetelstat的疗效及预算影响：来自临床与经济评审研究所加州技术评估论坛的综述报告摘要
Shahariar Mohammed Fahim,Jeffrey A Tice,Linda Luu et al.
Shahariar Mohammed Fahim et al.